In this article, we will discuss Golimumab and Liver Enzymes Elevations. So, let’s get started.
Golimumab and Liver Enzyme Elevations
There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers. In controlled Phase 3 trials of SIMPONI in patients with RA, PsA, and AS through Week 16, ALT elevations 2: 5 x ULN occurred in 0.2% of control-treated patients and 0.7% of SIMPONI-treated patients and ALT elevations 2: 3 x ULN occurred in 2% of control- treated patients and 2% of SIMPONI-treated patients. Since many of the patients in the Phase 3 trials were also taking medications that cause liver enzyme elevations (e.g., NSAIDs, MTX), the
relationship between SIMPONI and liver enzyme elevation is not clear.